WS #11746
AstraZeneca's Wainua fails Phase 3 trial, stock falls 6.2%.
AstraZeneca Drug Trial Failure
AstraZeneca's Wainua fails Phase 3 trial, stock falls 6.2%.
AstraZeneca's Wainua fails Phase 3 trial, stock falls 6.2%.
AstraZeneca's Wainua fails Phase 3 trial, stock falls 6.2%.